Note: This document contains side effect information about fluocinolone ophthalmic. Some of the dosage forms listed on this page may not apply to the brand name Iluvien.
Applies to fluocinolone ophthalmic: intraocular implant
Along with its needed effects, fluocinolone ophthalmic (the active ingredient contained in Iluvien) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking fluocinolone ophthalmic:
Some side effects of fluocinolone ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to fluocinolone ophthalmic: intravitreal implant
The most frequently reported side effects were cataract operation, cataract, and increased intraocular pressure.
Very common (10% or more): Cataract (82%), cataract operation (up to 80%), increased intraocular pressure (up to 34%), myodesopsia (21%), eye pain (15%), conjunctival hemorrhage (13%)
Common (1% to 10%): Glaucoma, vitreous hemorrhage, conjunctival hemorrhage, blurred vision, reduced visual acuity, vitreous floaters, trabeculectomy, vitrectomy, trabeculoplasty, eye irritation, conjunctivitis, corneal edema, foreign body sensation in eyes, ocular hyperemia, ocular discomfort, photophobia, anterior chamber cell, blepharitis, choroidal detachment, diplopia, hyphema
Uncommon (0.1% to 1%): Endophthalmitis, retinal vascular occlusion, optic nerve disorder, maculopathy, optic atrophy, conjunctival ulcer, iris neovascularization, retinal exudates, vitreous degeneration, vitreous detachment, posterior capsule opacification, iris adhesion, sclera thinning, eye discharge, eye pruritus, removal of extruded implant from sclera
Uncommon (0.1% to 1%): Extrusion of implant, implant in line of sight, procedural complication, procedural pain, device dislocation
Common (1% to 10%): Pneumonia, nasopharyngitis, sinusitis, upper respiratory tract infection, influenza, cough
Common (1% to 10%): Arthralgia, back pain, limb pain
Very common (10% or more): Headache (33%)
Common (1% to 10%): Dizziness
Common (1% to 10%): Vomiting, nausea
Common (1% to 10%): Rash
Very common (10% or more): Anemia (11%)
Common (1% to 10%): Renal failure
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Iluvien (www.drugs.com/mtm/iluvien.html).
March 27, 2020
March 27, 2020
March 28, 2020
March 27, 2020
March 24, 2020
March 26, 2020